Polio eradication, like all eradication efforts, is a gamble. If it fails, much of the money spent will have been wasted. If it succeeds, the world will reap a dividend. Success or failure and the magnitude of the dividend depend on a long chain of "weakest links." In this paper I identify these links and explain how the chain can be strengthened. A crucial vulnerability is the current plan to ...

INTRODUCTION The last wild poliovirus (WPV) case in Africa was reported in July 2014, thus underscoring the tremendous progress towards polio eradication worldwide. This study aimed to analyze the results of a seven-year surveillance of Acute Flaccid Paralysis (AFP) in the Democratic Republic of Congo (DRC) and to identify potential gaps that need to be addressed. METHODS Epidemiological and ...

Sabin-IPV (or sIPV, inactivated polio vaccine based on attenuated Sabin strains) is anticipated to replace the oral polio vaccine for the endgame in polio eradication. Optimization of sIPV production will lead to a better economically feasible vaccine. To assist process optimization, we studied Sabin type 1 poliovirus (PV) infection kinetics on Vero cells in controlled bioreactor vessels. The a...

THE LARGEST and most expensive medical experiment in history was carried out in 1954. Well over a million young children participated, and the immediate direct costs were over 5 million dollars. The experiment was carried out to assess the effectiveness, if any, of the Salk vaccine as a protection against paralysis or death from poliomyelitis. The study was elaborate in many respects, most prom...

AIM To estimate the incremental net benefits (INBs) of a hypothetical ideal vaccine with all of the advantages and no disadvantages of existing oral and inactivated poliovirus vaccines compared with current vaccines available for future outbreak response. METHODS INB estimates based on expected costs and polio cases from an existing global model of long-term poliovirus risk management. RESU...

A reading of ten relevant papers by Alexandre Jezierski provides evidence for the only attempt in Central Africa to develop a live oral polio vaccine (OPV) from growing reference wild polio strains to 210 passages in colobus monkey tissue culture, and experimental administration to about 25 humans. Chimpanzees were used as a human model, but their tissues or kidneys were absent from the passage...

The 20-year, U.S. $4 billion-dollar international effort to eradicate wild polioviruses now includes monovalent oral poliovirus type 1 vaccine (mOPV1), which was first given to 40 million children in India in April 2005. As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized world...

The production of the Salk vaccine polio virus by monkey kidney cells was generated using the synthetic tissue culture medium, Mixture 199. In this paper's retrospective assessment of this process, it was discovered that Mixture 199 was modified by the addition of ethanol to optimize animal cell survival based on experimentation that revealed a hormetic-like biphasic response relationship. This...

The Global Polio Eradication Initiative, launched in 1988, is close to achieving its goal. In 2015, reported cases of wild poliovirus were limited to just two countries - Afghanistan and Pakistan. Africa has been polio-free for more than 18 months. Remaining barriers to global eradication include insecurity in areas such as Northwest Pakistan and Eastern and Southern Afghanistan, where polio ca...

Born in 1944, I grew up in a world in which polio was both a gripping fear and real threat. Then in a matter of a few years-polio was eradicated by a vaccine developed by Jonas Salk. Later I learned that Salk's efforts were built on pioneering work of many others, including John Enders, Thomas Weller and Frederick Robbins (Nobelists, 1954), and David Bodian, who pioneered studies of polio patho...